On the other hand, randomized clinical trial data from a 5-year trial of insulin Glargine versus neutral protamine Hagedorn insulin did not provide evidence of enhanced cancer risk in the insulin Glargine arm12, 68. The gene discussed is INS; the disease is cancer.